Elanco Animal Health (ELAN) opened 2026 with Q1 revenue of about US$1.4b and basic EPS of US$0.11, alongside net income of US$57m, setting a cleaner profit picture against a still loss-making trailing twelve months. Over that period, basic EPS stands at a US$0.49 loss on revenue of US$4.9b and a net loss of US$242m. Over recent quarters the company has seen quarterly revenue move from US$1.02b in Q4 2024 to US$1.19b in Q1 2025 and then to US$1.37b in Q1 2026. Quarterly basic EPS shifted from US$0.02 in Q2 2025 to US$0.14 in Q1 2025, before landing at US$0.11 in the latest quarter, giving investors a mixed but improving view on how revenue scale is feeding through to the bottom line.

See our full analysis for Elanco Animal Health.

With the headline numbers on the table, the next step is to see how this Q1 report lines up with the widely followed narratives on Elanco's path to profitability and growth, and where the data starts to challenge those stories around margins and earnings quality.

US$1.4b Q1 revenue against slower 4.6% annual pace

• Q1 2026 revenue came in at about US$1.4b, while the latest trailing 12 month figure is US$4.9b. This lines up with the 4.6% annual revenue growth rate that has been slower than the reported 11.3% per year for the broader US market.
• Consensus narrative leans on new product launches and geographic expansion to support revenue, and the current numbers give mixed evidence for that view:
  • On one hand, revenue has moved from US$1.02b in Q4 2024 to US$1.19b in Q1 2025 and US$1.37b in Q1 2026. This is consistent with the idea that the product portfolio and expansion efforts are contributing to higher sales.
  • On the other, the 4.6% trailing revenue growth rate is still below the reported 11.3% US market average, so the data does not yet show the faster growth pace that more optimistic scenarios would like to see.

Loss making on US$4.9b sales, but Q1 swings to US$57m profit

• Over the trailing 12 months Elanco reported a net loss of US$242m on US$4.9b of revenue. Q1 2026 on its own shows net income of US$57m and basic EPS of US$0.11 compared with a loss of US$276m and basic EPS of US$0.56 loss in Q4 2025.
• Bulls argue that the path to profitability is opening up, and this quarter’s move into profit partly fits that story but with some clear caveats:
  • Support for the bullish view comes from the shift from quarterly losses in Q3 and Q4 2025, where net income was a US$34m loss and a US$276m loss, to two profitable quarters in Q1 2025 and Q1 2026 with net income of US$67m and US$57m respectively.
  • At the same time, the trailing 12 month loss of US$242m and a basic EPS loss of US$0.49 show that the business is not yet consistently profitable, which is at odds with the more confident bullish assumption that earnings are already on a firmly established upswing.

Have a look at how bullish investors join the dots between these profit swings and their longer term expectations 🐂 Elanco Animal Health Bull Case

“Attractive” P/S vs peers while stock sits below DCF fair value

• At a share price of US$26.18, Elanco is shown trading on a P/S of 2.7x compared with the cited peer average of 4.4x and industry average of 5.5x. It is also below the provided DCF fair value of about US$35.98, which implies a sizeable valuation gap against both peers and that DCF figure.
• Bears highlight that continued losses justify a discount, and the current data supports parts of that concern but not all of it:
  • The trailing 12 month net loss of US$242m and basic EPS loss of US$0.49 back the cautious view that profitability risks are still front and center, which can help explain why the P/S multiple sits below peers and industry.
  • However, the combination of positive quarterly EPS in Q1 2025 and Q1 2026 and a share price that is below both the 29.43 analyst target and the US$35.98 DCF fair value shows that the discount is being measured against improving recent profitability as well as against those value estimates.

If you want to see how cautious investors frame that discount against the ongoing losses, it is worth reading their full argument 🐻 Elanco Animal Health Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Elanco Animal Health on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With all that in mind, does the current mix of profits, losses and valuation match your own read of the story, or feel a step off? Act quickly, stress test the upside narrative against the underlying figures and see how those potential rewards stack up for you with the 3 key rewards

Explore Alternatives

Elanco's trailing 12 month loss of US$242m, basic EPS loss of US$0.49 and slower 4.6% revenue growth rate highlight profitability and growth risks.

If that mix of ongoing losses and below market growth feels uncomfortable, it is worth immediately comparing it with companies in the 74 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.